Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ≥65 years of age at the time of consent~* Participating or participated in Study C4591001, received 2 doses of 30 µg BNT162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of BNT162b2~* Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease~* Adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study~* Previous clinical or microbiological diagnosis of COVID-19~* Previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation~* Previous vaccination with any coronavirus vaccine, other than those received in Study C4591001~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Coadministration Group (Type: EXPERIMENTAL): Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
- 20vPnC-only Group (Type: ACTIVE_COMPARATOR): Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
- BNT162b2-only Group (Type: ACTIVE_COMPARATOR): Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).